MoonLake's Claims Under Controversy as Investors Face Major Losses

MoonLake Under Legal Spotlight Amidst Controversial Claims

MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX) is currently in hot water as concerns rise over the efficacy claims surrounding its drug, SLK. This scrutiny follows a staggering 90% decline in the company's stock price, which plummeted from $61.99 on September 29, 2025, to just $6.24. The legal firm Hagens Berman is leading a securities class action lawsuit against the company, urging affected investors to step forward before the upcoming deadline of December 15, 2025.

The Underlying Issues

The case hinges somewhat on the alleged discrepancies between the company's optimistic public declarations regarding SLK and the actual outcomes reported from clinical trials. Reed Kathrein, a partner at Hagens Berman who is spearheading the litigation, emphasizes the importance of aligning public statements with the reality of the clinical data provided by the company. This investigation is particularly focused on a perceived concealment of adverse findings about SLK's clinical performance and whether it can genuinely differentiate itself from competitors, such as BIMZELX.

Key Allegations

1. Molecular Target Disclosure: One major allegation is that MoonLake failed to adequately inform investors that SLK and BIMZELX, a traditional monoclonal antibody approved by the FDA, target the same molecular identifiers—specifically, interleukin-17 (IL-17). This raises serious questions about SLK's competitive market positioning.
2. Nanobody Superiority Claims: The company's assertions that the unique Nanobody structure of SLK would promise better clinical efficacy, especially regarding treating hidradenitis suppurativa (HS), are also being contested. Investors are questioning whether this Nanobody actually shows any significant advantage over existing treatments, as previously claimed.
3. Financial Fallout: With the stock experiencing such a dramatic drop, investors are understandably concerned. The potential legal repercussions hinge on whether these undisclosed trial results affected the market performance of MLTX shares, entitling investors to seek restitution for their losses.

Legal Options for Investors

Hagens Berman is prepared to assist investors who acquired shares of MLTX between March 10, 2024, and September 29, 2025, and experienced losses due to these alleged misleading practices. The firm has a strong track record, with over $2.9 billion secured in settlements for clients in similar litigation, indicating a robust approach to corporate accountability.

Next Steps

Investors are encouraged to reach out to Hagens Berman to learn more about their rights and legal options as the deadline approaches. It’s crucial for those affected to act quickly to ensure their voices are heard in this class action. Hagens Berman invites all investors who believe they have been adversely impacted by MoonLake’s actions to submit their claims before the December 15 deadline.

For more specific inquiries, affected individuals may contact Reed Kathrein directly or submit details regarding their stock losses through Hagens Berman's secure forms. Additionally, potential whistleblowers with non-public knowledge regarding MoonLake are urged to consider the SEC Whistleblower program, which may offer rewards for significant contributions to the investigation.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is a globally recognized law firm specializing in complex litigation and a focus on protecting civil rights and the rights of investors. The firm has a proven commitment to ensuring accountability from corporations and protecting investors from corporate negligence.

In light of the unfolding situation, investors will be watching closely to see how the legal proceedings impact MoonLake and the broader biotech sector.

For continual updates on this case and more on investor rights, follow Hagens Berman on their social media channels and their official website.